Form 4: Amicus Therapeutics Director Eiry Roberts Boosts Stake with RSU Grant and Stock Option Acquisition

Amicus Therapeutics, Inc. Director Eiry Roberts acquired 20,414 shares of common stock through Restricted Stock Units and 74,872 stock options on June 5, 2025, increasing her beneficial ownership.

Summary

• Eiry Roberts, a Director of Amicus Therapeutics, Inc. (FOLD), reported transactions on June 5, 2025.
• She acquired 20,414 shares of common stock in the form of Restricted Stock Units (RSUs). These RSUs were granted at a price of $0.0 and are set to vest in full on the one-year anniversary of the grant date.
• Following this transaction, her direct beneficial ownership of common stock increased to 76,275 shares.
• Additionally, she acquired 74,872 stock options with an exercise price of $5.96 per share. These options will vest and become exercisable on the one-year anniversary of the grant date and expire on June 5, 2035.

Sentiment

Score: 7

Explanation: The filing indicates a director increasing their stake through equity compensation, which is generally a positive signal of confidence in the company's future, though it's a routine compensation event rather than a direct investment.

Positives

• Director Eiry Roberts increased her beneficial ownership in Amicus Therapeutics, indicating confidence in the company's future.
• The acquisition of Restricted Stock Units (RSUs) and stock options aligns the director's interests with long-term shareholder value.

Future Outlook

The vesting schedule for both the Restricted Stock Units and stock options, set for the one-year anniversary of the grant date (June 5, 2026), indicates a future alignment of the director's compensation with the company's performance over the coming year.

Industry Context

This Form 4 filing reflects a standard equity compensation grant to a director in the biotechnology or pharmaceutical industry, a common practice to incentivize long-term commitment and align interests with shareholders. Such grants are typical for directors who are not executive officers and receive a portion of their compensation in equity.

Comparison to Industry Standards

• The grant of Restricted Stock Units (RSUs) and stock options to a non-executive director like Eiry Roberts is a common compensation practice across the biotechnology and pharmaceutical sectors, similar to companies such as Biogen Inc. or Gilead Sciences, Inc., which frequently use equity to attract and retain board talent.
• The vesting schedule of one year for both RSUs and options is a standard short-to-medium term incentive structure, comparable to practices seen at peer companies, aiming to ensure continued engagement and oversight from board members.
• The exercise price of $5.96 for the options, likely based on the market price at the time of grant, is typical for at-the-money options granted as part of a compensation package.

Stakeholder Impact

• Shareholders: The increase in director ownership through equity compensation aligns the director's interests with those of shareholders, potentially fostering better long-term decision-making.

Next Steps

• The acquired Restricted Stock Units (RSUs) are expected to vest on the one-year anniversary of the grant date (June 5, 2026).
• The acquired stock options are expected to vest and become exercisable on the one-year anniversary of the grant date (June 5, 2026).

Key Dates

Recommendation

Keywords

Amicus Therapeutics, FOLD, Form 4, Insider Trading, Director, Eiry Roberts, Restricted Stock Units, RSU, Stock Options, Equity Compensation, Beneficial Ownership